Fintel reports that on December 23, 2024, Scotiabank initiated coverage of Thermo Fisher Scientific (NYSE:TMO) with a Sector Perform recommendation.
Analyst Price Forecast Suggests 26.66% Upside
As of December 23, 2024, the average one-year price target for Thermo Fisher Scientific is $665.20/share. The forecasts range from a low of $591.05 to a high of $805.35. The average price target represents an increase of 26.66% from its latest reported closing price of $525.20 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Thermo Fisher Scientific is 48,229MM, an increase of 13.83%. The projected annual non-GAAP EPS is 26.52.
What is the Fund Sentiment?
There are 3,919 funds or institutions reporting positions in Thermo Fisher Scientific. This is an increase of 60 owner(s) or 1.55% in the last quarter. Average portfolio weight of all funds dedicated to TMO is 0.46%, an increase of 31.66%. Total shares owned by institutions increased in the last three months by 0.13% to 386,525K shares. 
The put/call ratio of TMO is 1.08, indicating a bearish outlook.
What are Other Shareholders Doing?
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 12,106K shares representing 3.17% ownership of the company. In its prior filing, the firm reported owning 12,062K shares , representing an increase of 0.36%. The firm increased its portfolio allocation in TMO by 5.45% over the last quarter.
Price T Rowe Associates holds 10,973K shares representing 2.87% ownership of the company. In its prior filing, the firm reported owning 9,925K shares , representing an increase of 9.55%. The firm increased its portfolio allocation in TMO by 18.98% over the last quarter.
VFINX - Vanguard 500 Index Fund Investor Shares holds 10,004K shares representing 2.62% ownership of the company. In its prior filing, the firm reported owning 9,797K shares , representing an increase of 2.07%. The firm increased its portfolio allocation in TMO by 5.11% over the last quarter.
Capital World Investors holds 9,326K shares representing 2.44% ownership of the company. In its prior filing, the firm reported owning 9,518K shares , representing a decrease of 2.07%. The firm increased its portfolio allocation in TMO by 4.19% over the last quarter.
Capital Research Global Investors holds 8,188K shares representing 2.14% ownership of the company. In its prior filing, the firm reported owning 8,237K shares , representing a decrease of 0.61%. The firm increased its portfolio allocation in TMO by 5.31% over the last quarter.
Thermo Fisher Scientific Background Information
(This description is provided by the company.)
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $25 billion. Its Mission is to enable our customers to make the world healthier, cleaner and safer. Whether the customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, the company is here to support them. Its global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
